Back to Authors

Abousaida, Belal

https://orcid.org/0000-0001-5418-5221

Mayo Clinic

University of Kansas Medical Center

Citations 2

Systemic antitumor immune response of doped yttria nanoscintillators under low-dose x-ray irradiation
Sahin, Onur , Mackeyev, Yuri , Vijay, Geraldine V. , Roy, Soumyabrata , Ashokkumar, Meiyazhagan , Zahra, Yasmin , Tezcan, Okan , Gonzalez, Valeria , Abousaida, Belal , Wagner, Holden R. , FERNANDES, P. S. , Mowzoon-Mogharrabi, Riaz , Venkatesulu, Bhanu Prasad , Hsieh, Cheng‐En , Kim, Joseph Byung-Kyu, Raghuram, Subhiksha, Zhang, Xiang , Miller, Kristen A. , Gao, Guanhui , Cho, Sang Hyun , Papineni, Rao V. , Ajayan, Pulickel M., Krishnan, Sunil , Meiyazhagan, Ashokkumar , Fernandes, Pearl , Kim, Joseph B K, Papineni, Rao V L , Krishnan, Sunil , Hsieh, Rodney Cheng-En , Gonzalez, Valeria V , Mackeyev, Yuri , Mowzoon-Mogharrabi, Riaz , Singh, Pankaj Kumar , Ajayan, Pulickel M.

Science Advances | March 26, 2025 | Volume: 11 | Issue: 13 | Pages: No page available

10.1126/sciadv.adr4008 Get It

Inadequate light penetration in tissues restricts photodynamic therapy to treating only superficial tumors. To enable x-ray–excited photodynamic therapy (XPDT) that targets deep-seated tumors, we synthesized a nanoscintillator-photosensitizer complex containing 5% Eu-doped Y 2 O 3 fluorescing at 611 nanometers and decorated with SiO 2 containing the scintillation-coupled photosensitizer methylene blue and a polyethylene glycol coating [PEGylated Y 2 O 3 :Eu@SiO 2 -methylene blue (pYSM)]. When irradiated, pYSMs generate singlet oxygen species in vitro, causing cytotoxicity with hallmarks of immunogenic cell death (calreticulin translocation to the cell membrane). Intravenously administered pYSMs home passively to pancreatic tumor xenografts and, upon 10 gray irradiation, cause significant tumor regression ( P < 0.01). On combining XPDT with anti-PD1 immunotherapy, a distant nonirradiated tumor also regresses via an increase in intratumoral activated CD8 + cytotoxic T cells. Collectively, we advance a systemically delivered XPDT strategy that mediates an antitumor effect in both irradiated and nonirradiated (abscopal) tumors when coupled with immunotherapy, converting an immunologically “cold” tumor to an immunologically “hot” tumor.
Pancreatic tumor microenvironmental acidosis and hypoxia transform gold nanorods into cell-penetrant particles for potent radiosensitization
Rauta, Pradipta Ranjan , Mackeyev, Yuri , Sanders, Keith L. , Kim, Joseph Byung-Kyu, Gonzalez, Valeria , Zahra, Yasmin , Shohayeb, Muhammad A. , Abousaida, Belal , Vijay, Geraldine V. , Tezcan, Okan , Liopo, Anton V. , Carter, Rickey E. , Sanders, Keith , Gonzalez, Valeria V , Carter, Rickey E , Krishnan, Sunil , Mackeyev, Yuri , Derry, Paul J. , Zubarev, Eugene R. , Singh, Pankaj K.

Science Advances | November 11, 2022 | Volume: 8 | Issue: 45 | Pages: No page available

10.1126/sciadv.abm9729 Get It

Coating nanoparticles with stealth epilayers increases circulation time by evading opsonization, macrophage phagocytosis, and reticuloendothelial sequestration. However, this also reduces internalization by cancer cells upon reaching the tumor. We designed gold nanorods (GNRs) with an epilayer that retains stealth properties in circulation but transforms spontaneously in the acidotic tumor microenvironment to a cell-penetrating particle. We used a customized stoichiometric ratio of l -glutamic acid and l -lysine within an amphiphilic polymer of poly( l -glutamic acid-co- l -lysine), or P(Glu-co-Lys), to effect this transformation in acidotic environments. P(Glu-co-Lys)-GNRs were internalized by cancer cells to facilitate potent in vitro radiosensitization. When administered intravenously in mice, they accumulate in the periphery and core of tumors without any signs of serum biochemical or hematological alterations, normal organ histopathological abnormalities, or overt deterioration in animal health. Furthermore, P(Glu-co-Lys)-GNRs penetrated the tumor microenvironment to accumulate in the hypoxic cores of tumors to potently radiosensitize heterotopic and orthotopic pancreatic cancers in vivo.